← Back to patent-cliff list
CAS 23078-57-1
2,5-dibromo-4,4-dimethylcyclopentane-1,3-dione
Codes: TASE-027
Application context (from source-drug indications)
Breast cancerTaselisibBladder cancerTaselisibMultiple myelomaTaselisibLung cancerTaselisibLiver cancerTaselisibCervical cancerTaselisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Taselisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→4-bromo-2-fluorobenzonitrile→4-bromo-2-fluoro-N-hydroxybenzimidamide→ethyl propiolate→ethyl 3-((4-bromo-2-fluorobenzimidamido)oxy)acrylate→ethyl 2-(4-bromo-2-fluorophenyl)-1H-imidazole-4-carboxylate→1,3-dioxolan-2-one→ethyl 2-(4-bromo-2-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazole-4-carboxylate→9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylic acid→9-bromo-N-(1-iminoethyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide→ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate→ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate→2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid→ethyl 2-bromo-2-methylpropanoate→1H-pyrazole→ethyl 2-methyl-2-(1H-pyrazol-1-yl)propanoate→2,5-dibromo-4,4-dimethylcyclopentane-1,3-dione→ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.